-
公开(公告)号：US07037918B2
公开(公告)日：2006-05-02
申请号：US10309535
申请日：2002-12-03
申请人： John M. Nuss , Stephen D. Harrison , David B. Ring , Rustum S. Boyce , Sean P. Brown , Dane A. Goff , Kirk W. Johnson , Keith B. Pfister , Savithri Ramurthy , Paul A. Renhowe , Lynn Seely , Sharadha Subramanian , Allan S. Wagman , Xiaohui A. Zhou
发明人： John M. Nuss , Stephen D. Harrison , David B. Ring , Rustum S. Boyce , Sean P. Brown , Dane A. Goff , Kirk W. Johnson , Keith B. Pfister , Savithri Ramurthy , Paul A. Renhowe , Lynn Seely , Sharadha Subramanian , Allan S. Wagman , Xiaohui A. Zhou
IPC分类号： A61K31/505 , A61K31/535 , A61K31/47 , A61K31/475 , A61K31/52
CPC分类号： C07D213/74 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/14 , C07D417/12
摘要： New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
-
公开(公告)号：US06489344B1
公开(公告)日：2002-12-03
申请号：US09336098
申请日：1999-06-18
申请人： John M. Nuss , Stephen D. Harrison , David B. Ring , Rustum S. Boyce , Sean P. Brown , Dane A. Goff , Kirk W. Johnson , Keith B. Pfister , Savithri Ramurthy , Paul A. Renhowe , Lynn Seely , Sharadha Subramanian , Allan S. Wagman , Xiaohui A. Zhou
发明人： John M. Nuss , Stephen D. Harrison , David B. Ring , Rustum S. Boyce , Sean P. Brown , Dane A. Goff , Kirk W. Johnson , Keith B. Pfister , Savithri Ramurthy , Paul A. Renhowe , Lynn Seely , Sharadha Subramanian , Allan S. Wagman , Xiaohui A. Zhou
IPC分类号： C07D40104
CPC分类号： C07D213/74 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/14 , C07D417/12
摘要： New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
摘要翻译： 提供了新的嘧啶或吡啶类化合物，体外抑制糖原合成酶激酶（GSK3）活性和体内GSK3介导的病症治疗的组合物和方法。 本发明的方法，化合物和组合物可以单独使用或与其它药理活性剂组合用于治疗由GSK3活性介导的病症，例如治疗糖尿病，阿尔茨海默病和其他神经变性疾病，肥胖症，动脉粥样硬化 心血管疾病，原发性高血压，多囊卵巢综合征，X综合征，缺血，创伤性脑损伤，双相情感障碍，免疫缺陷或癌症。
-
公开(公告)号：US20120129777A1
公开(公告)日：2012-05-24
申请号：US13111746
申请日：2011-05-19
申请人： Kirk W. Johnson
发明人： Kirk W. Johnson
CPC分类号： A61K31/727 , A61K31/731 , A61K31/737 , A61K38/36 , A61K38/37 , A61K38/4846 , A61K45/06 , Y10S514/834 , A61K2300/00
摘要： Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or, with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
摘要翻译： 公开了使用非抗凝血硫酸多糖（NASP）作为促凝剂治疗出血性疾病的方法。 NASP可作为单一药物或彼此组合施用，或与其它药物（如因子VII，VIII和IX）一起施用以促进止血。 特别地，描述了使用NASP治疗出血性疾病，包括先天性凝血障碍，获得性凝血障碍和创伤诱导的出血性病症。
-
4.发明申请公开(公告)号：US20110117213A1
公开(公告)日：2011-05-19
申请号：US12948545
申请日：2010-11-17
申请人： Kazuko MATSUDA , Yuichi Iwaki , Kirk W. Johnson
发明人： Kazuko MATSUDA , Yuichi Iwaki , Kirk W. Johnson
IPC分类号： A61K31/165 , A61K31/56 , A61K33/06 , A61K31/24 , A61K31/44 , A61K31/46 , A61K31/573 , A61P11/00 , A61P11/08
CPC分类号： A61K31/165 , A61K31/138 , A61K31/24 , A61K31/44 , A61K31/46 , A61K31/56 , A61K31/573 , A61K33/06 , A61K45/06 , A61K2300/00
摘要： The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.
摘要翻译： 本发明提供了改善经历急性呼吸道发作的个体的一种或多种临床结果的方法。 急性呼吸道发作可能包括急性可逆性支气管痉挛，严重急性支气管痉挛或哮喘急性加重。 该方法包括对患有急性呼吸道感染的个体施用与护理标准（SOC）治疗方案相结合的有效量的卧肾上腺素或其药学上可接受的盐。
-
公开(公告)号：US07767654B2
公开(公告)日：2010-08-03
申请号：US11140504
申请日：2005-05-27
申请人： Kirk W. Johnson
发明人： Kirk W. Johnson
IPC分类号： A61K31/715 , A01N43/04 , A61K31/70
CPC分类号： A61K31/727 , A61K31/731 , A61K31/737 , A61K38/36 , A61K38/37 , A61K38/4846 , A61K45/06 , Y10S514/834 , A61K2300/00
摘要： Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
摘要翻译： 公开了使用非抗凝血硫酸多糖（NASP）作为促凝剂治疗出血性疾病的方法。 NASP可以作为单一药剂或彼此组合施用，或与其它药物（例如因子VII，VIII和IX）一起施用以促进止血。 特别地，描述了使用NASP治疗出血性疾病，包括先天性凝血障碍，获得性凝血障碍和创伤诱导的出血性病症。
-
公开(公告)号：US07383158B2
公开(公告)日：2008-06-03
申请号：US10125364
申请日：2002-04-16
申请人： Robert E. Krocker , Terence D. Baier , Merle A. Renaud , Paul C. Rentmeester , Robert M. Swanson , Patrick J. Wilson , Kirk W. Johnson
发明人： Robert E. Krocker , Terence D. Baier , Merle A. Renaud , Paul C. Rentmeester , Robert M. Swanson , Patrick J. Wilson , Kirk W. Johnson
CPC分类号： G05B15/02 , G05B2219/2642
摘要： A system for servicing a computer controlled machine comprising: a computer controlled machine including a device operable to perform a function, a controller controlling the operation of that device, and a data access port for transferring data and commands from the controller; and a service tool operably connected to the data access port, the service tool including a remote communications capability, a computer, and diagnostics and graphing software; and an expert observer system operably linked to the remote communications capability of the service tool and including historical machine data, machine sales information, software revisions for the controller, additional diagnostics software, and an expert observer capable of providing a mentor capability to the operator of a service tool.
摘要翻译： 一种用于维修计算机控制机器的系统，包括：计算机控制机器，包括可操作以执行功能的设备，控制该设备的操作的控制器以及用于从控制器传送数据和命令的数据访问端口; 以及可操作地连接到所述数据访问端口的服务工具，所述服务工具包括远程通信能力，计算机和诊断和图形软件; 以及可操作地与服务工具的远程通信能力相关联的专家观察器系统，并且包括历史机器数据，机器销售信息，用于控制器的软件修订，附加诊断软件和能够向操作者提供导师能力的专家观察者 一个服务工具。
-
公开(公告)号：US5998622A
公开(公告)日：1999-12-07
申请号：US112562
申请日：1998-07-09
IPC分类号： A61P25/04 , A61K31/00 , A61K31/437 , A61K31/444 , A61K31/4545 , A61P25/06 , A61P43/00 , C07D471/04
CPC分类号： C07D471/04 , A61K31/00 , A61K31/437 , A61K31/444 , A61K31/4545
摘要： This invention provides 5-HT.sub.1F agonists of Formula I; ##STR1## where A-B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.
摘要翻译： 本发明提供式I的5-HT1F激动剂; 其中A-B，X和R如说明书中所定义。 本发明还包括使用式I化合物的药物制剂以及使用这些化合物或组合物治疗与5-HT1F活化相关的病症的方法。 本发明还提供了可用于制备式I化合物的中间体。
-
![Enantiomeric compositions of 2-amino-1-(2-isopropylpyrazolo[1,5-α]pyridin-3-yl)propan-1-one and related methods](/abs-image/US/2012/02/21/US08119657B2/abs.jpg.150x150.jpg)
8.发明授权Enantiomeric compositions of 2-amino-1-(2-isopropylpyrazolo[1,5-α]pyridin-3-yl)propan-1-one and related methods 失效2-氨基-1-（2-异丙基吡唑并[1,5-a]吡啶-3-基）丙-1-酮的对映体组合物及相关方法公开(公告)号：US08119657B2
公开(公告)日：2012-02-21
申请号：US12820993
申请日：2010-06-22
IPC分类号： A61K31/44 , C07D491/02 , C07D498/02
CPC分类号： C07D471/04 , A61K31/437 , C07B2200/07
摘要： Enantiomerically pure (S)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one, (S)-AV1013, is a candidate therapeutic for treating neuropathic pain, addiction behavior and drug withdrawal symptoms. Also described are methods for preparing and using (S)-AV1013, its pharmaceutically acceptable salts as well as pharmaceutically acceptable formulations of the same.
摘要翻译： 对映体纯的（S）-2-氨基-1-（2-异丙基吡唑并[1,5-a]吡啶-3-基）丙-1-酮，（S）-AV1013是治疗神经性疼痛的候选治疗剂， 成瘾行为和戒毒症状。 还描述了制备和使用（S）-AV1013，其药学上可接受的盐以及其药学上可接受的制剂的方法。
-
公开(公告)号：US20110275664A1
公开(公告)日：2011-11-10
申请号：US13064485
申请日：2011-03-28
IPC分类号： A61K31/437 , A61P25/36
CPC分类号： A61K31/437 , A61K45/06 , A61K2300/00
摘要： The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior. In addition, methods are provided for preventing or inhibiting relapse in human subjects having a history of methamphetamine addiction or dependence by the administration of an effective amount of ibudilast.
摘要翻译： 本发明涉及使用异丁司特治疗成瘾症，包括药物和行为成瘾。 特别地，异丁司特用于减少与成瘾相关的多巴胺介导的奖励，并且在停用上瘾的药物使用或行为后治疗戒断综合征。 此外，提供了通过施用有效量的异丁司特来预防或抑制具有甲基苯丙胺成瘾史或依赖性的人类受试者的复发方法。
-
公开(公告)号：US07915285B2
公开(公告)日：2011-03-29
申请号：US11527757
申请日：2006-09-26
IPC分类号： A61K31/4745
CPC分类号： A61K31/00 , A61K31/437 , A61K31/4745 , A61K45/06 , A61K2300/00
摘要： The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior.
摘要翻译： 本发明涉及使用异丁司特治疗成瘾症，包括药物和行为成瘾。 特别地，异丁司特用于减少与成瘾相关的多巴胺介导的奖励，并且在停用上瘾的药物使用或行为后治疗戒断综合征。
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.064 秒)
